In mouse models, the addition of PD-1 inhibition to intralesional PV-10 therapy resulted in a reduction in the tumor burden and an increase in tumor-infiltrating lymphocytes (TIL), resulting in improved response rates [49]. This evidence concerns the gene PDCD1 and neoplasm.